From: Prognostic value of lymphocyte-to-monocyte ratio in ovarian cancer: a meta-analysis
Author | Year | Country | Ethnicity | Follow-up (months) | Treatment | Age (years) | No. of patients | Stage | Cut-off value | Survival analysis | Analysis | NOS score |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Temraz | 2014 | Lebanon | Caucasian | 24 | Mixed | 65 (43–88) | 68 | Mixed | 2.81 | OS/RFS | UV | 8 |
Lee | 2015 | UK | Caucasian | NA | Surgery | 75 (65–81) | 226 | Early | 1.8 | OS | MV | 7 |
Zhang | 2015 | China | Asian | 50.8 | Mixed | 65 (30–78) | 124 | Mixed | 4 | OS | MV | 8 |
Yoshida | 2015 | Japan | Asian | 72 (27.6–111.6) | Mixed | 72 (43–91) | 181 | Mixed | 3.51 | OS | MV | 7 |
Lucca | 2016 | Austria | Caucasian | NA | Surgery | 68 (61–74) | 310 | Early | 3.3 | OS | MV | 6 |
D’Andrea | 2017 | Austria | Caucasian | 42.4 (18.3–85.1) | Surgery | 67 (60–73) | 4198 | Mixed | 3.5 | OS/RFS/CSS | MV | 8 |
Miyake | 2017 | Japan | Asian | 22 (10–64) | Mixed | 72 (61–77) | 117 | Mixed | 3.3 | OS/CSS | UV | 6 |
Rajwa | 2018 | Poland | Caucasian | 14 (7–40) | Surgery | NA | 144 | Mixed | 2.44 | OS/CSS | MV | 8 |
Wang | 2018 | China | Asian | NA | Mixed | 63 (20–85) | 270 | Early | 4 | RFS | UV | 7 |